

Special Issue

Cancer Genetics and Genomics

Message from the Guest Editors

Cancer is one of the most complex diseases, and its early diagnosis and effective treatment is a permanent challenge. Both genomic and genetic approaches have decisively contributed to a better characterization of the malignant phenotype, the discovery of new biomarkers, and targeted therapies, especially with the advent of new technologies such as next-generation sequencing at both DNA and RNA levels. However, new data are necessary to complete the big puzzle of molecular alterations that underlie cancer development and its treatment resistance. Moreover, new insight into cancer–host cohabitation needs to be decoded in order to better understand if and how the corrupted host cells could be targeted to improve cancer treatment management. One useful approach in cancer management is to use liquid biopsy for identifying new biomarkers such as specific methylation or mutation patterns, or the presence of gene expression alteration of circulating RNAs (miRNAs, circRNAs, lncRNAs). As of this Special Issue, we cordially invite you to contribute one or more research or review papers focused on genomic or genetic approaches in cancer.

Guest Editors

Dr. Ovidiu Balacescu

Department of Genetics, Genomics and Experimental Pathology, The Oncology Institute "Prof. Dr. Ion Chiricuta", 400015 Cluj-Napoca, Romania

Dr. Adrian Pavel Trifa

Department of Genetics, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania and The Oncology Institute "Prof. Dr. Ion Chiricuta", 400015 Cluj-Napoca, Romania

Deadline for manuscript submissions

closed (30 November 2022)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/110950

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).